Alnylam Pharmaceuticals, Inc. (ALNY)
After hours:
| Previous close | 138.31 |
| Open | 130.20 |
| Bid | 128.00 x 800 |
| Ask | 136.36 x 1300 |
| Day's range | 130.00 - 137.92 |
| 52-week range | 125.08 - 212.00 |
| Volume | |
| Avg. volume | 831,991 |
| Market cap | 16.315B |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.13 |
| Earnings date | 09 Feb 2022 - 14 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 209.55 |
- Business Wire
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass., January 21, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, met all secondary endpoints measured at 18 months in patients with hATTR amyloidosis with polyneuropathy, including statistically significant improvements in neuropathy impairment, quality of life (QoL
- Business Wire
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
CAMBRIDGE, Mass., January 14, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 18-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, at the Société Francophone du Nerf Périphérique (SFNP) Annual Meeting. The meeting will be held January 21-22 in Pa
- Bloomberg
Alnylam’s CEO Is Ready to Take Over From a Biotech Legend
(Bloomberg) -- Yvonne Greenstreet was sitting on a plane at Boston Logan International Airport waiting to take off in 2018 when U.S. regulators approved Alnylam Pharmaceuticals Inc.’s first drug, Onpattro. The chief operating officer grabbed her carry-on from the overhead bin, ran off the plane and bolted to the office so she could celebrate the accomplishment with her colleagues. Most Read from BloombergCypriot Scientist Says Deltacron Covid Variant Isn’t ErrorWorld’s Biggest Crypto Fortune Beg
